News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Nektar Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Biotech Beach
The Day In Review: Gilead Sciences (Foster City, CA) Pays $365 Million For Corus Pharma, Inc.
July 20, 2006
·
1 min read
Biotech Beach
The Day In Review: Diabetes News Rules
June 13, 2006
·
1 min read
Biotech Beach
The Day In Review: Vertex Pharmaceuticals Incorporated Reveals Positive Hep C Data
May 22, 2006
·
1 min read
The Week In Review: From Optimism To Pessimism In Three Short Weeks
October 19, 2005
·
1 min read
Ten Drugs To Watch
October 19, 2005
·
3 min read
Bated Breath For Inhaled Insulin
October 19, 2005
·
1 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
December 16, 2025
·
15 min read
Press Releases
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
December 16, 2025
·
2 min read
Press Releases
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
December 8, 2025
·
5 min read
Press Releases
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
November 10, 2025
·
12 min read
Press Releases
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
November 6, 2025
·
13 min read
Press Releases
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 in London
October 31, 2025
·
1 min read
Press Releases
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
October 28, 2025
·
2 min read
Press Releases
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
October 23, 2025
·
8 min read
Press Releases
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
September 18, 2025
·
12 min read
Press Releases
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
September 9, 2025
·
7 min read
